[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-checkpoint-inhibitor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-checkpoint-inhibitor":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,48,72,96,124,149,179,200,224,253,278,300,329,363,385,407,431,452,475],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100619043","phase-2-intestinal-low-dose-radiotherapy-plus-immunochemotherapy-for-conversion-of-borderline-resectableunresectable-esophageal-squamous-cell-carcinoma-100619043",false,"NCT07339488","Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable\u002FUnresectable Esophageal Squamous Cell Carcinoma","Efficacy and Safety of Combining Intestinal Low Dose Radiotherapy Plus Tislelizumab and Chemotherapy for Conversion of Borderline Resectable\u002FUnresectable Esophageal Squamous Cell Carcinoma","ILDR-03","Inclusion Criteria:\n\n1. Patients voluntarily enroll in this study, sign an informed consent form, and demonstrate good compliance.\n2. Age ≥18 years and ≤75 years; both sexes are eligible.\n3. ECOG performance status score of 0-1.\n4. Pathologically confirmed esophageal squamous cell carcinoma (ESCC) prior to surgery.\n5. Thoracic esophageal cancer.\n6. Unresectable lesions, defined as: T4 stage; marginally resectable T3 stage (invading other organs, e.g., trachea, bronchus, or aorta not ruled out by imaging); presence or absence of unresectable lymph nodes or metastatic lymph nodes invading adjacent organs; presence or absence of supraclavicular lymph node metastasis; or clinically confirmed unresectable disease by the surgeon.\n7. No prior history of anti-tumor treatment, including chemotherapy, hormonal therapy, radiotherapy, or immunotherapy.\n8. Baseline laboratory requirements (within 7 days prior to enrollment):\n\n   Hematology:\n   1. Hb≥90 g\u002FL (no transfusion within 14 days)\n   2. NEUT ≥1.5×10⁹\u002FL\n   3. PLT ≥100×10⁹\u002FL\n   4. WBC≥3×10⁹\u002FL\n\n   Biochemistry:\n   1. ALT and AST≤2.5×ULN\n   2. TBIL≤1.5×ULN\n   3. SCr≤1.5×ULN; or CrCl≥60 mL\u002Fmin Coagulation: APTT, INR, and PT≤1.5×ULN Thyroid function: TSH≤ULN (if abnormal, FT3\u002FFT4 levels should also be considered; eligible if FT3\u002FFT4 are normal) Echocardiography: LVEF≥50%\n9. Female subjects need to agree to use contraception during the study and for 6 months post-study; serum pregnancy test negative within 7 days prior to enrollment; non-lactating. Male subjects must agree to use contraception during the study and for 6 months post-study.\n10. No psychological, familial, social, or geographical factors that may impair protocol adherence.\n11. Other parameters meet general clinical trial enrollment criteria.\n12. The subject or authorized representative has read, fully understands the patient information sheet, and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with distant metastases other than supraclavicular lymph node metastases.\n2. Presence or high risk of esophageal perforation.\n3. Patients with contraindications to radiotherapy or immune checkpoint inhibitor (ICI) therapy.\n4. Patients who previously experienced unacceptable toxicity after receiving ICI therapy.\n5. Patients with a history of thoracoabdominal\u002Fpelvic radiotherapy within 6 months prior to enrollment.\n6. Adverse reactions from prior anti-tumor treatment have not recovered to CTCAE v5.0 grade≤1 (excluding toxicities deemed by the investigator to pose no safety risk, such as fatigue or alopecia).\n7. Subjects with active, uncontrolled systemic bacterial, viral, or fungal infections despite optimal treatment.\n8. Respiratory depression, airway obstruction, or tissue hypoxia.\n9. Severe cardiac disease (i.e., NYHA functional class II or higher).\n10. Markedly abnormal liver or kidney function (i.e., indicators \\>3 times the upper limit of normal).\n11. Active hepatitis B, hepatitis C, HIV, or syphilis.\n12. Active brain disease or central nervous system\u002Fmeningeal metastases with significant symptoms, or impaired decision-making capacity.\n13. Hypersensitivity to drugs included in the trial.\n14. Drug and\u002For alcohol abuse.\n15. Pregnant or lactating women.\n16. Concurrent participation in another therapeutic clinical trial.\n17. Major surgical procedure within 30 days prior to enrollment.\n18. Use of antibiotics, antifungals, antivirals, or antiparasitics within 4 weeks prior to registration.","ALL","18 Years","75 Years",{"count":21,"type":22},43,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","Esophageal cancer (EC) ranks among the leading malignant gastrointestinal tumors globally in terms of both incidence and mortality. Cases of EC in China account for over 50% of the global total, with squamous cell carcinoma being the primary pathological type. Locally advanced EC (LAEC), particularly cases where radical surgical resection is not feasible, exhibits high recurrence rates and low 5-year survival rates. However, studies have shown that patients with LAEC who undergo comprehensive treatment followed by surgery experience significantly prolonged survival and improved quality of life compared to those who do not receive surgical intervention.\n\nCurrent conversion treatment regimens under investigation include: chemotherapy alone, chemoradiotherapy, immunotherapy combined with chemotherapy, and immunotherapy combined with chemoradiotherapy-each of these approaches has distinct advantages and limitations. Immunochemotherapy has emerged as a current research focus: it not only demonstrates significantly superior efficacy compared to chemotherapy alone but also exhibits lower cumulative toxicity than radiotherapy-combined conversion regimens, resulting in a more favorable overall benefit-risk ratio. As such, it represents the most promising conversion treatment strategy.\n\nRetrospective and prospective clinical studies have shown that low-dose radiotherapy targeting the small intestine can enhance the anti-tumor response of immune checkpoint inhibitors (ICIs) in patients with advanced solid tumor, prolong their overall survival, and increase the incidence of the abscopal effect. Further mechanistic investigations have revealed that intestinal low-dose radiotherapy (ILDR) may augment the immune cancerous lethality by modulating the gut microbiota and their metabolic profiles.\n\nBased on the findings from these preliminary studies, the current research plans to conduct a prospective phase II single-arm clinical trial to investigate the efficacy and safety of ILDR combined with immunochemotherapy as conversion therapy in patients with borderline resectable or unresectable esophageal squamous cell carcinoma (BR\u002FUR ESCC). This research plans to enroll at least 39 evaluable cases or a total of 43 cases in two seperated stages, focusing on patients with thoracic BR\u002FUR ESCC. Patients will receive a single fraction of ILDR with a mean dose of 1 Gy, concurrently with 3 cycles of albumin-bound paclitaxel (260 mg\u002Fm² on day 1), cisplatin (75 mg\u002Fm² on day 1), and tislelizumab (200 mg on day 1). The efficacy and safety of the treatment will be evaluated throughout the study.",[28,29,30,31,32,33,34],"Borderline Resectable Carcinoma","Unresectable Cancer","Esophageal Squamous Cell Carcinoma (ESCC)","Immune Checkpoint Inhibitor","Chemotherapy","Radiotherapy","Tislelizumab","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-18","ACTUAL",{"date":41,"type":39},"2025-12-05",{"date":43,"type":22},"2028-11-01",{"name":45,"class":46},"Chuangzhen Chen","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100642768","phase-2-thymosin-alpha-1-combined-with-anti-pd-1-monoclonal-antibody-in-elderly-patients-with-advanced-melanoma-100642768","NCT07644897","Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma","Inclusion Criteria:\n\n1. Aged 60 years or older;\n2. Diagnosis of malignant melanoma confirmed by pathological histology or cytology examination.\n3. According to the 8th edition of AJCC staging, patients with unresectable stage III or IV melanoma;\n4. One or more lesions evaluable by RECIST1.1 standards.\n5. The Eastern Cooperative Oncology Group (ECOG) scoring system in the United States has a score range of 0-2.\n6. Total bilirubin ≤1.5× upper limit of normal (ULN); AST and AST \\\u003C2.5× upper limit of normal (ULN).(No liver metastasis), or \\\u003C5 times the upper limit of normal (ULN) (with liver metastasis);\n7. Patients with recurrent metastasis who have not previously received immunotherapy such as PD-1, PD-L1, CTLA-4 antibodies，also allowed for the enrollment of patients who had used adjuvant\u002Fneoadjuvant therapies\n\n   * If the adjuvant or neoadjuvant treatment plan includes PD(L)-1 or CTLA-4 monoclonal antibodies, it is required that only those who progress more than 6 months after the end of the treatment plan can be included in the study group.\n   * If the adjuvant or neo-adjuvant treatment plan does not include PD(L)-1 or CTLA-4 monoclonal antibodies, patients who progress during the adjuvant treatment are allowed to participate in the study.\n8. Has signed the informed consent form, able to comply with the study protocol and follow-up plan.\n\nExclusion Criteria:\n\n1. Received treatment involving PD-1, PD-L1, or CTLA-4 antibody regimen within the past 6 months;\n2. Patients who have received treatment with thymosin, thymopentin, or thymosin a-1d within 3 months prior to enrollment.\n3. Presence of symptomatic central nervous system (CNS) metastases and\u002For carcinomatous meningitis. For subjects with previously treated CNS metastases, if the subject's condition is stable (no evidence of radiographic progression for at least weeks prior to the first administration of the study intervention, and all neurological symptoms have returned to baseline), repeat radiographic examination confirms no evidence of new brain metastases or enlargement of existing brain metastases, and no need for steroid treatment for at least 14 days prior to the first administration of the study intervention, they may participate in the study.\n4. Patients with active systemic autoimmune diseases requiring systemic treatment (i.e., using immunomodulators, corticosteroids, or immunosuppressants). Replacement therapies (such as thyroxine, insulin, or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered systemic treatment.\n5. Has a history of immunodeficiency, including testing positive for HIV, or suffering from other acquired or congenital immunodeficiency diseases, or has a history of organ transplantation and bone marrow transplantation.\n\n6）Allergic to the investigational drug or its components; 7）Presence of active infection requiring systemic treatment; 8) Uncontrolled internal medical complications, such as unstable congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accidents, and hemodynamically unstable arrhythmias, etc.\n\n9\\) The investigator deems them unsuitable for inclusion.","60 Years",{"count":56,"type":22},55,[25],"Primary Objective:\n\nTo evaluate the effectiveness of Thymosin Alpha-1 combined with PD-1 monoclonal antibody in elderly patients with advanced melanoma .\n\nSecondary Objective:\n\nTo evaluate the safety and tolerability of adenpeptide-α1 combined with PD-1 antibody in elderly patients with advanced melanoma .\n\nStudy Design：Open-label, single-arm, non-controlled clinical trial.\n\nPrimary Inclusion Criteria:\n\n1. Age ≥60 years old;\n2. Pathologically confirmed as inoperable or metastatic melanoma;\n3. one or more lesions evaluable by RECIST1.1 standards.\n4. The Eastern Cooperative Oncology Group (ECOG) scoring system in the United States scores from 0-2;\n\nMain exclusion criteria:\n\n1. Received treatment with a regimen containing PD-1, PD-L1, or CTLA-4 antibodies within the past 6 months;\n2. Received thymosin class drug treatment within 3 months before signing the informed consent.\n3. Symptomatic, untreated central nervous system metastases. Treatment： Thymosin Alpha 1 1.6mg, sc，QD，d1-7;1.6mg, sc， three times per week, d8-21. Each 21 days is considered one cycle, for a total of 12 weeks.\n\nAnti-PD-1 monoclonal antibody (Toripalimab) 240mg per dose,ivdrip，Q3W，4 cycles.\n\nPrimary study endpoints:\n\nObjective Response Rate (ORR: CR+PR)\n\nSecondary study endpoints:\n\nProgression-Free Survival (PFS), Duration of Response (DOR), Overall Survival (OS) Adverse Events (AEs)",[60,61,31],"Melanoma","Immune-related Adverse Event","2026-06-08",{"date":64,"type":39},"2026-06-12",{"date":66,"type":39},"2023-05-30",{"date":68,"type":22},"2027-09-30",{"name":70,"class":46},"Sun Yat-sen University",2,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100511615","phase-3-ic-plus-low-dose-radiation-plus-cadonilimab-in-lanpc-100511615","NCT05941741","IC Plus Low-dose Radiation Plus Cadonilimab in LANPC","Induction Chemotherapy Combined With Low-dose Radiation Plus Cadonilimab in Loco-regionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Open-label, Randomized Controlled Phase III Clinical Trial","Inclusion Criteria:\n\n* Newly histologic diagnosis of nasopharyngeal non-keratinizing carcinoma (WHO II\u002FIII);\n* All genders, range from 18-70 years old;\n* ECOG score 0-1;\n* Clinical stage T4N1M0 and T1-4N2-3M0 (AJCC\u002FUICC 8th);\n* Not received radiotherapy, chemotherapy and other anti-tumor treatment (including immunotherapy);\n* No contraindications to chemotherapy, radiotherapy or immunotherapy;\n* Adequate organ function: white blood cell count ≥ 4×109\u002FL, neutrophile granulocyte count ≥ 1.5×109\u002FL, hemoglobin ≥ 9g\u002FL, platelet count ≥ 100×109\u002FL; alanine aminotransferase or aspartate aminotransferase \\\u003C 2.5×upper limit of normal; blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* Sign the consent form.\n\nExclusion Criteria:\n\n* Distant metastases;\n* Keratinized squamous cell carcinoma or basal cell like squamous cell carcinoma;\n* Have or are suffering from other malignant tumors;\n* Participating in other clinical trials;\n* Pregnancy or lactation;\n* Have uncontrolled cardiovascular disease;\n* Severe complication, eg, uncontrolled hypertension;\n* Mental disorder;\n* Drug or alcohol addition;\n* Do not have full capacity for civil acts.","70 Years",{"count":81,"type":22},380,[83],"PHASE3","This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.",[86,31,33,32],"Nasopharyngeal Carcinoma","2026-05-06",{"date":89,"type":39},"2026-05-11",{"date":91,"type":39},"2024-01-10",{"date":93,"type":22},"2029-12",{"name":70,"class":46},3,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":95},"100597473","phase-2-spatially-fractionated-radiotherapy-combined-with-immunotherapy-for-advanced-solid-tumors-100597473","NCT07058948","Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors","A Phase II Prospective, Open-Label, Single-Arm Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With Immunotherapy in Patients With Advanced Solid Tumors","SFRT-IM-P2","\\*\\*Inclusion Criteria:\\*\\*\n\n1. Signed informed consent.\n2. Histologically or cytologically confirmed malignant solid tumor.\n3. Advanced solid tumor unsuitable for surgery as determined by a multidisciplinary tumor board or consulting physicians.\n4. No available standard therapy or inability to tolerate it, with imaging and clinical assessment showing stable disease (SD) or progressive disease (PD).\n5. Age ≥18 years on the day of signing informed consent.\n6. No prior radiotherapy to the proposed site, or last radiotherapy ≥6 months ago.\n7. KPS score ≥70.\n8. At least one measurable lesion per RECIST 1.1. Previously irradiated lesions qualify only if significant progression post - radiotherapy.\n9. Life expectancy \\>3 months.\n10. Adequate organ and bone marrow function:\n\n    * Marrow: ANC ≥1.5×10⁹\u002FL, platelets ≥80×10⁹\u002FL, hemoglobin ≥9 g\u002FdL;\n    * Liver: Total bilirubin ≤1.5× upper limit of normal (ULN), ALT\u002FAST ≤1.5× ULN;\n    * Kidney: Serum creatinine ≤1.5× ULN or creatinine clearance ≥50 ml\u002Fmin, blood urea nitrogen ≤200 mg\u002FL;\n    * Coagulation: INR ≤1.5× ULN, PTT ≤1.5× ULN.\n11. Recovery from prior therapy - related adverse events (≤Grade 1 or baseline).\n12. Willingness to use appropriate contraception.\n13. No radiotherapy contraindications as judged by the radiation oncologist.\n14. Agreement to receive both immunotherapy and radiotherapy.\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n1. Active central nervous system (CNS) metastases, carcinomatous meningitis, or spinal cord compression.\n2. Severe comorbidities such as myocardial infarction within 6 months, severe arrhythmias, or psychosis that may affect treatment completion or result in a life expectancy of \\\u003C3 months.\n3. Evidence of interstitial lung disease or active\u002Fnon - infectious pneumonia (e.g., drug - induced, radiation - induced) requiring steroid treatment.\n4. History of pulmonary fibrosis, pulmonary artery hypertension, or severe irreversible airway obstruction.\n5. Presence of peripheral neuropathy.\n6. Severe organ dysfunction (e.g., hepatic, cardiopulmonary failure) that is likely to make radiotherapy intolerable.\n7. Known allergy to study drugs or excipients, or a history of severe allergic reaction to any PD - 1 monoclonal antibody.\n8. Serious infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteremia, or severe pneumonia; or receipt of oral or intravenous antibiotics within 2 weeks prior to study treatment. Patients receiving prophylactic antibiotics (e.g., for urinary tract infections or chronic obstructive pulmonary disease exacerbations) are eligible.\n9. Known or suspected active autoimmune disease (e.g., uveitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, thyroiditis). Exceptions: patients with vitiligo, cured childhood asthma; patients with well - controlled type 1 diabetes on insulin.\n10. History of allogeneic organ transplant (except corneal) or allogeneic hematopoietic stem cell transplant.\n11. Pregnant or breastfeeding women.\n12. Any other condition that the investigator deems a valid reason for disqualification based on the protocol.",{"count":105,"type":22},30,[25],"Lattice radiation therapy (LRT) is a spatially fractionated radiotherapy technique that creates alternating high - and low - dose areas within a tumor to enhance local control and reduce toxicity to surrounding tissues. This study aims to evaluate the effectiveness and safety of combining LRT with immunotherapy in patients with advanced or metastatic solid tumors, through a Phase II clinical trial. Patients will receive specific - dose irradiation using a medical linear accelerator. Within the GTV of the largest tumor, spheres (0.5 - 3 cm in diameter) will be created as high - dose targets (LRT targets), spaced 2.0 - 5.0 cm apart. The LRT targets must be drawn within the GTV, avoiding blood vessels, with a margin of at least 1 cm from the GTV margin, and a volume ratio of 1% - 10% of the GTV. For a single lesion, the D95 of the GTV will be ≥1 Gy\u002Ffraction, and the D95 of the LRT target will be 8 - 12 Gy\u002Ffraction, with minimal possible single - fraction doses to organs at risk. All other irradiated metastases will receive low - dose radiotherapy (100 - 300 cGy × 5 fractions), except for brain and bone metastases, which will be treated with palliative radiotherapy as per clinical routine. Immunotherapy will be administered during or within one week after radiotherapy.",[109,33,31,110],"Solid Cancers","Lung Cancer",[112,113,114],"spatially fractionated radiotherapy","solid cancers","immune checkpoint inhibitor","2026-04-27",{"date":117,"type":39},"2026-04-29",{"date":119,"type":39},"2025-07-01",{"date":121,"type":22},"2027-07-01",{"name":123,"class":46},"Tianjin Medical University Cancer Institute and Hospital",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":131,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100622120","adjuvant-anti-pd-1-therapy-in-resected-hepatocellular-carcinoma-100622120","NCT07379489","Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma","Efficacy of Postoperative Adjuvant PD-1 Inhibitors Guided by a Deep Learning Model: a Multicenter, Prospective Cohort Study","Inclusion Criteria:\n\n* Aged between 18 and 75;\n* achieved complete tumor resection;\n* histological verification of HCC;\n* liver function classified as Child-Pugh grade A or B;\n* No other serious systemic disease or organ dysfunction.\n\nExclusion Criteria:\n\n* history of other malignancies or recurrent HCC;\n* extrahepatic metastasis;\n* prior treatments for HCC;\n* ongoing severe postoperative complications;\n* mixed or other types of liver cancer;\n* received other adjuvant therapy.",{"count":132,"type":22},300,"OBSERVATIONAL","Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.",[136,137,138,31],"HCC","Adjuvant Therapy","Recurrence","NOT_YET_RECRUITING","2026-01-23",{"date":142,"type":39},"2026-01-30",{"date":144,"type":22},"2026-01-31",{"date":146,"type":22},"2031-12-31",{"name":148,"class":46},"Tongji Hospital",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":160,"studyType":133,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":71},"100533585","analysis-of-pd-l1-tmb-msi-and-ctdna-dynamics-to-predict-and-monitor-response-to-immunotherapy-in-metastatic-cancer-100533585","NCT06227728","Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.","Analysis of PD-L1, TMB, CTDNA in Immunotherapy Response Monitoring and Prediction in Advancer Lung Cancer Treatment.","PTC-IMPACT","Inclusion Criteria:\n\n* 18 years and older, both genders.\n* Patients are diagnosed with stage IV cancer (lung, colorectal, breast, liver, gastric…) and indicated for ICI (first or second line). Concurrent chemotherapy with ICI is allowed.\n* FFPE\u002FFNA sample is available.\n* Compliant with treatment protocol.\n* Patients consented to participate in the study.\n\nExclusion Criteria:\n\n* Patients already started ICI before enrollment.\n* Consolidation ICI (eg. Durvalumab).\n* Patients already started chemotherapy before enrollment.\n* Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol.\n* Patients did not agree to participate in the studies.","80 Years",{"count":159,"type":22},50,"3 Years","This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.",[163,164,165,166,167,168,31],"Non Small Cell Lung Cancer","Breast Cancer","Colorectal Cancer","Gastric Cancer","Liver Cancer","Advanced Cancer","2026-01-14",{"date":171,"type":39},"2026-01-16",{"date":173,"type":39},"2024-03-22",{"date":175,"type":22},"2026-12-31",{"name":177,"class":178},"Gene Solutions","INDUSTRY",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100613487","phase-2-prag-1-plus-prag-therapy-in-advanced-solid-tumors-a-prospective-clinical-trial-prag-100-100613487","NCT07267234","PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histologically confirmed treatment-naïve or relapsed\u002Fmetastatic advanced solid malignancies with no standard treatment option per current clinical guidelines or intolerance to standard therapy; measurable metastatic lesions ≥1 cm (by RECIST criteria); absolute lymphocyte count (ALC) below lower limit of normal (LLN).\n3. No history of congestive heart failure, unstable angina, or unstable cardiac arrhythmias within the past 6 months.\n4. ECOG performance status 0-3; estimated life expectancy ≥3 months.\n5. No history of significant hematologic, cardiac, pulmonary, hepatic, or renal dysfunction.\n6. Baseline AST ≤3×ULN and ALT ≤3×ULN (≤5×ULN for hepatocellular carcinoma or liver metastases); creatinine ≤3×ULN.\n7. Capacity to comprehend study procedures and voluntarily provide written informed consent.\n\nExclusion Criteria:\n\n1. History of other malignancies within the past 5 years, except for adequately treated non-melanoma skin cancer or cervical carcinoma in situ.\n2. Uncontrolled epilepsy, central nervous system disorders, or psychiatric disorders that, in the investigator's judgment, may interfere with informed consent or treatment adherence.\n3. Clinically significant active cardiac disease, including symptomatic coronary artery disease, NYHA Class II or higher congestive heart failure, severe arrhythmias requiring pharmacological intervention, or myocardial infarction within the past 12 months.\n4. History of solid organ transplant requiring ongoing immunosuppressive therapy.\n5. Known significant active infection, or significant hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction, or other serious uncontrolled comorbidities as determined by the investigator.\n6. Allergy to any component of the study drug(s).\n7. History of immunodeficiency, including HIV infection, acquired or congenital immunodeficiency disorders, solid organ transplant, or chronic immunosuppressive therapy for immune-related conditions.\n8. Active or latent tuberculosis infection confirmed by positive T-SPOT.TB test or chest X-ray findings suggestive of tuberculosis.\n9. Any other condition that, in the investigator's clinical judgment, may compromise study participation or safety.",{"count":186,"type":22},65,[25],"The goal of this clinical trial is to learn if a combination treatment using PRaG-1 Cordycepin Tablets with radiation therapy, immune-boosting injections, and immunotherapy drugs can help patients with advanced solid tumors. It will also assess safety. The main questions it aims to answer are:\n\nDoes this treatment improve immune function and slow tumor growth? What side effects or risks occur during treatment?\n\nParticipants will:\n\nTake PRaG-1 Cordycepin Tablets (a natural compound derived from Cordyceps fungus) orally: higher dose for 7 days before radiation, then lower daily dose for 2 weeks Receive targeted radiation therapy to the tumor area (5-12 Gy total in 2-3 sessions) Get daily immune-boosting injections (GM-CSF) for 7 days starting with radiation Receive immunotherapy drugs (PD-1\u002FPD-L1 inhibitors) within one week after radiation Have blood drawn and small tumor tissue samples taken before and after the first two treatment cycles for immune analysis All participants will receive this combination treatment; there is no placebo or alternative treatment group in this study.",[190,191,33,31],"Solid Cancer","Lymphopenia","2025-11-24",{"date":41,"type":39},{"date":195,"type":22},"2025-12-01",{"date":197,"type":22},"2027-09-01",{"name":199,"class":46},"Second Affiliated Hospital of Soochow University",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":206,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":4},"100607461","study-on-the-relationship-between-opioid-drugs-and-the-therapeutic-efficacy-of-immunotherapy-100607461","NCT07188857","Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy","Inclusion Criteria:\n\n* Aged ≥ 18 years; Histologically confirmed advanced NSCLC (Stage IIIb-IV); Need to receive ICIs treatment; Accompanied by moderate or severe pain (NRS score ≥ 4); Need to use opioid drugs for pain management; Able to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* Suffering from severe dysfunction of important organs such as heart, liver, and kidney; Suffering from mental illness or receiving treatment with psychotropic drugs; Pregnant or lactating women; Participating in other clinical trials; Allergic to opioid drugs.",{"count":207,"type":22},100,"Relationship between pain and the efficacy of immunotherapy: Does the degree of pain control affect the therapeutic efficacy of ICIs? Does the use of opioid drugs independently affect the efficacy of immunotherapy?",[210,31,211],"Pain Management","Opioid",[213,214,114],"pain management","opioids","2025-09-16",{"date":217,"type":39},"2025-09-23",{"date":219,"type":22},"2025-09-17",{"date":221,"type":22},"2027-10-01",{"name":223,"class":46},"Hubei Cancer Hospital",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":231,"targetDuration":4,"studyType":23,"phases":233,"briefSummary":234,"conditions":235,"keywords":240,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":47},"100607289","phase-3-adjuvant-radiotherapy-of-sintilimab-versus-tace-for-hcc-100607289","NCT07186621","Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC","Adjuvant Radiotherapy Combined With Sintilimab Versus Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma With Narrow Margins and High-Risk Features Following Resection: A Multi-center Phase III Randomized Controlled Trial","Inclusion Criteria:\n\n1. R0 resection of hepatocellular carcinoma (HCC) with a surgical margin \\\u003C1 cm (determined by postoperative pathology, surgical records, and imaging).\n2. Within 4 months after curative resection.\n3. High-Risk Recurrence Factors (at least one required in addition to narrow margin): (1) Microvascular invasion (MVI) positive, tumor thrombus, or satellite nodules (2) Preoperative AFP \\>400 ng\u002FmL (3) Tumor \\>5 cm with incomplete capsule\n4. ≥18 and ≤80 years old.\n5. ECOG score 0-1.\n6. Child-Pugh Class: A5, A6, or B7.\n7. Postoperative Contrast-enhanced MRI of the liver must be performed to exclude intrahepatic residual lesions.\n8. HBV DNA and HCV RNA status do not affect eligibility, but if HBV DNA positive and\u002For HCV RNA positive: ALT must be \\\u003C1.5× upper limit of normal (ULN). Antiviral therapy must be initiated.\n9. Liver Function Tests (LFTs): ALT ≤2.5× ULN (if HBV\u002FHCV positive, ALT ≤1.5× ULN). If ALT ≤1.5× ULN, AST ≤6× ULN (excluding AST elevation due to myocardial infarction). If ALT 1.5-2.5× ULN, AST ≤2.5× ULN.\n10. No significant ECG abnormalities and no severe cardiac dysfunction.\n11. Serum creatinine (CRE) and BUN ≤2.5× ULN.\n12. Hb≥80g\u002FL，ANC≥1.0×109 \u002FL，PLT≥40×109 \u002FL.\n13. Written informed consent obtained.\n\nExclusion Criteria:\n\n1. Vp3 or Vp4 portal vein tumor thrombus (PVTT) or Vv2\u002FVv3 inferior vena cava (IVC) tumor thrombus on preoperative imaging.\n2. Previous anti-HCC therapies, including but not limited to: targeted therapy (e.g., tyrosine kinase inhibitors), immune checkpoint inhibitors (e.g., PD-1\u002FPD-L1 inhibitors) or systemic chemotherapy\n3. Distant metastasis before randomization.\n4. Moderate to severe ascites unresponsive to medical management.\n5. History of other malignancies, except: carcinoma in situ，early-stage papillary thyroid cancer or basal cell carcinoma of the skin\n6. Previous radiotherapy involving the abdomen.\n7. Significant cardiac, renal, or other major organ dysfunction.\n8. Active Autoimmune Disease or Psychiatric Disorders.\n9. HIV Infection.\n10. Pregnant or breastfeeding women.\n11. Currently enrolled in another interventional clinical trial.",{"count":232,"type":22},286,[83],"This study is an open-label, randomized controlled, multicenter, phase III clinical trial",[236,237,31,238,239],"Hepatocellular Carcinoma (HCC)","Radiotherapy, Adjuvant","TACE","Narrow Margin",[241,242,243,244,238],"hepatocellular carcinoma","radiotherapy","narrow margin","sintilimab",{"date":246,"type":39},"2025-09-22",{"date":248,"type":39},"2025-07-10",{"date":250,"type":22},"2028-11-30",{"name":252,"class":46},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":47},"100535699","phase-2-a-study-of-multimodal-radiotherapy-for-renal-cell-carcinoma-progressed-after-prior-immunotherapy-100535699","NCT06255223","A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy","An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Multimodal Radiotherapy in the Treatment of Renal Cell Carcinoma Progressed After Prior Immunotherapy","Inclusion Criteria:\n\n* Renal cell carcinoma confirmed histologically or cytopathologically, including unresectable or recurrent metastatic renal cell carcinoma.\n* Subject's previous treatment: Disease progression or intolerance following prior treatment with 1-2 systemic therapies (at least one regimen containing immune checkpoint inhibitors, including combined VEGFR-TKI drugs), And patients who have progressed within 12 months of prior immunoadjuvant or neoadjuvant therapy; According to the evaluation of attending physicians and professional radiotherapy doctors, it meets the standard of radiotherapy.\n* Patients can tolerate sequential immunotherapy while receiving radiation therapy.\n* At least two or more metastases at different sites are considered observable according to RECIST v1.1.\n* Subjects have fully understood and voluntarily signed an informed Consent form (ICF).\n* ECOG 0-1 points.\n* Major organs are functioning well.\n* Willing and able to comply with study plan visits, treatment laboratory tests, sample retention, and other procedures.\n* Fertile women must voluntarily use a highly effective contraceptive method (e.g., oral, injectable or implantable, barrier method, spermicide and condom, or intrauterine device) from the study period to ≥120 days after the last dose and have negative urine or serum pregnancy test results ≤7 days prior to enrolment.\n* Male patients who are not sterilized must voluntarily use highly effective contraception during the study period until ≥120 days after the last dose.\n\nExclusion Criteria:\n\n* A history of malignancies other than the disease studied within the past 5 years, other than malignancies that are expected to be cured with treatment (including but not limited to adequately treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or breast ductal carcinoma in situ treated with radical surgery).\n* Systemic treatment with other antitumor agents, including targeted agents, immunotherapy agents and their combination regimens (eligible for inclusion after 5 half-lives), local antitumor therapy, or clinical investigational drug or device therapy, was administered 4 weeks prior to the first study.\n* Previous history of radiation therapy at any site or in any mode.\n* Had major surgery (as judged by the investigator) within 4 weeks prior to the first trial or was convalescing.\n* A history of severe drug allergy, including but not limited to antibody drugs.\n* Patients with contraindications to restart immunotherapy.\n* A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation may require long-term adrenal corticosteroid therapy.\n* Patients with thyroid, suprarenal, or hypopituitarism that can be controlled with hormone replacement therapy alone, type 1 diabetes, and psoriasis or vitiligo that do not require systemic treatment are eligible to participate in this study.\n* Toxicity did not resolve after previous antitumor therapy, i.e. regression to baseline, prescribed grade 0 to 1 (except alopecia) as defined in NCI-CTCAE 5.0, or to the levels specified in the inclusion\u002Fexclusion criteria. Irreversible toxicity (such as hearing loss) that could reasonably be expected not to be aggravated by the drug under study could be included in this study.\n* Have central nervous system metastases and\u002For cancerous meningitis.\n* A known history of clinically significant liver disease.\n* Accompanied by uncontrolled third space effusion requiring repeated drainage, such as pleural effusion, ascites, pericardial effusion, etc.\n* In the first study, systemic corticosteroids or other immunosuppressive drugs were administered within 14 days prior to medication.\n* Patients with any severe or uncontrolled disease.\n* Have or have a suspected presence of active autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.\n* Renal failure requires hemodialysis or peritoneal dialysis.\n* A history of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation.\n* History of live attenuated vaccine vaccination within 4 weeks prior to administration or expected live attenuated vaccine vaccination during the study period was studied for the first time.\n* People who have a history of psychotropic substance abuse and cannot abstain or have a history of mental disorders.\n* Pregnant or lactating women.\n* Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities, as determined by the investigator, that may increase the risks associated with study participation or that may interfere with the interpretation of the study results.",{"count":261,"type":22},35,[25],"The objective of this single-center clinical study was to evaluate the disease control rate(DCR) and safety of multimodal radiotherapy in the treatment of patients with renal cell carcinoma (RCC) progressed after prior immunotherapy.",[265,33,31],"Renal Cell Carcinoma",[267,268],"RCC","Multimodal radiotherapy","2025-08-26",{"date":271,"type":39},"2025-09-03",{"date":273,"type":39},"2023-12-15",{"date":275,"type":22},"2026-09-01",{"name":277,"class":46},"Jinling Hospital, China",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":71},"100497204","efficacy-and-safety-of-super-hyperfractionation-pulse-radiotherapy-combined-with-icis-for-advanced-nsclc-100497204","NCT05754203","Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC","Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With Immune Checkpoint Inhibitor for Advanced Non-small Cell Lung Cancer.","Inclusion Criteria\n\n1. Informed consent has been signed and, in the judgment of the investigator, the patient is able to comply with the study protocol and sign a written informed consent.\n2. Participants diagnosed with stage IIIB or above non-small cell lung cancer confirmed by histopathology (whether newly diagnosed or not) meet the requirements of SBRT radiotherapy (mass limited, less than 5 cm) and immune checkpoint inhibitor therapy (according to CSCO guidelines).\n3. Age ≥ 18 and less than 75.\n4. Eastern Cooperative Oncology Group Performance Status Score (ECOG PS) 0-3.\n\nExclusion Criteria\n\n1. The participant's compliance is poor and the test regulations are violated.\n2. Dysfunction of important organs of liver and kidney, such as myocardial infarction, angina pectoris, and significant increase of liver transaminase.\n3. Any disease requiring systemic treatment with corticosteroids or other immunosuppressive drugs within 14 days prior to enrollment.\n4. Serious infection within 4 weeks before enrollment, including but not limited to hospitalization due to infection complications, bacteremia or severe pneumonia.\n5. Severe chronic or active infections (including tuberculosis infection) requiring systemic (oral or intravenous) antibiotic therapy within 14 days before enrollment.\n6. Participants with untreated chronic hepatitis B or HBV carriers with hepatitis B virus (HBV) DNA ≥ 500 IU\u002FmL, or patients with active hepatitis C virus (HCV) should be excluded. Note: Inactive hepatitis B, HBsAg carriers, treated and stable hepatitis B carriers (HBV DNA \\\u003C 500 IU\u002FmL), and cured hepatitis C patients can be included in the group.\n7. Known history of HIV infection.\n8. Receive any other investigational drug treatment or participate in other clinical trials within 28 days.\n9. There are no contraindications to stereotactic radiotherapy and immune checkpoint inhibitors.",{"count":286,"type":22},40,[288],"NA","Investigators intend to combine low-dose hypersensitivity with high-dose immunopotentiation effect, and use super-hyperfractionation pulse radiotherapy, which is expected to achieve the effect of in situ vaccine that can enhance tumor killing, protect normal tissues, reduce immune cell damage and enhance tumor immunogenicity at the same time, and play a stronger immunopotentiation effect in combined immunotherapy. Thereby inducing a stronger abscopal effect of radiotherapy.",[110,31,33],"2025-07-11",{"date":293,"type":39},"2025-07-14",{"date":295,"type":39},"2023-08-01",{"date":297,"type":22},"2026-03-01",{"name":299,"class":46},"Xinqiao Hospital of Chongqing",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":308,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":318,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":47},"100501526","liver-cancer-and-immunotherapy-in-the-liquid-biopsy-era-100501526","NCT05810402","Liver Cancer and Immunotherapy in the Liquid Biopsy Era","Liver Cancer and Immunotherapy : Clinical Relevance of LIquid BioPSY","LILIPSY","Inclusion Criteria:\n\n* Patients of at least 18 years old,\n* Patients with advanced hepatocellular carcinoma or HCC with indication for first-line PD-1 or PD-L1 immunotherapy in MDT, without prior systemic therapy,\n* The diagnosis of HCC is established according to imaging criteria (LI-RADSv2018 criteria) or after histological evidence,\n* Advanced HCC defined by BCLC stages B and C,\n* Patients with oral consent.\n\nExclusion Criteria:\n\n* Administration of a previous systemic anti-tumor treatment (immunotherapy or chemotherapy or targeted therapy)\n* No personal history of neoplasia in the previous 5 years\n* No personal history of systemic inflammatory diseases\n* No immunosuppressive treatment or treatment that could modify immunity (anti-TNF...)\n* No affiliation or non-beneficiary of a Social Security system;\n* Vulnerable persons according to article L1121-6 of the CSP ;\n* Persons of full age who are protected or unable to give their consent according to article L1121-8 of the CSP;\n* Pregnant or breastfeeding women according to article L1121-5 of the CSP.\n* Non-inclusion due to follow-up difficulties (transfer, insufficient motivation, poor compliance, priority associated pathology in care, etc.)",true,{"count":310,"type":22},60,[288],"The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy.\n\nThe main questions it aims to answer are:\n\n* Is multi-omic liquid biopsy approach able to identify a strong predictive biomarker of immunotherapy efficiency?\n* Is there a correlation between tissue biopsy (PD-L1 tissue level of expression) and liquid biopsy (detection of CTC expressing PD-L1) in HCC patients?\n\nParticipants blood will be collected at several time points.",[314,315,316,31,317],"Hepatocellular Carcinoma","BCLC Stage B Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Liquid Biopsy",[314,319,31,317,320],"BCLC Stage B and C","Precision Medicine","2025-07-07",{"date":248,"type":39},{"date":324,"type":39},"2023-06-28",{"date":326,"type":22},"2027-05",{"name":328,"class":46},"University Hospital, Montpellier",{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":336,"minAge":18,"maxAge":79,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":340,"conditions":341,"keywords":349,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":47},"100531268","safety-assessment-of-concurrent-radiotherapy-and-novel-systemic-therapy-for-breast-cancer-100531268","NCT06197581","Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer","RADIOCOM","Inclusion Criteria:\n\nECOG 0-2. Aged 18-70 years old. Pathologically diagnosed as breast cancer. Need to receive radiotherapy according to guidelines. Radiotherapy target volume included chest wall\u002Fbreast with or without lymph node regions.\n\nNeed to receive one of the following therapies according to guidelines, capetabine, CDK4\u002F6 inhibitor, PARP inhibitor , ICIs , HER2 inhibitors.\n\nExclusion Criteria:\n\nMale breast cancer. Allergy to the upper medicines before. Will receive trastuzumab alone during and\u002For after radiotherapy. With severe other disease.","FEMALE",{"count":338,"type":22},148,[288],"Radiation therapy is a crucial part in the comprehensive treatment of breast cancer. In recent years, emerging systemic treatment regimens such as HER 2 inhibitors, CDK 4\u002F6 inhibitors, PARP inhibitors, capecitabine and PD1 inhibitors have greatly improved the prognosis of breast cancer and has become the standard treatment for specific populations. A considerable number of patients require both radiotherapy and maintenance systemic therapy. However, it is not clear whether systemic therapy should be synchronized or suspended in radiotherapy，despite that previous basic research shows that some molecular drug therapy and radiotherapy has a clear synergy mechanism. There is an agent need for a definite evidence to evaluate the safety of synchronous treatment, to support clinical diagnosis and treatment and the next step of comprehensive treatment. The implementation of the new radiotherapy technology represented by IMRT takes into account the prescription dose homogenization and the minimization of normal tissue dosage, which provides a certain basis for the combination therapy. Based on the above conditions, this study intends to enroll patients between 18 and 70 years old with chest wall \u002F breast ± lymphatic drainage area and requiring capecitabine, CDK 4\u002F 6 inhibitor, HER2 targeted therapy or immunotherapy. Radiation and novel systemic therapies would be delivered concurrently. The study aimed at evaluating the safety of combined treatments.",[342,343,344,31,345,346,347,348],"Breast Cancer, Familial Male","Radiotherapy; Complications","Chemotherapeutic Toxicity","CDK4\u002F6 Inhibitor","Trastuzumab","Pertuzumab","PARP Inhibitor",[164,33,350,351,346,347,352,353,354],"Adverse events","Capecitabine","Immune checkpoint inhibitor","CDK4\u002F6 inhibitor","PARP inhibitor","2024-08-19",{"date":357,"type":39},"2024-08-21",{"date":359,"type":39},"2024-01-12",{"date":361,"type":22},"2027-01-15",{"name":252,"class":46},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":79,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":47},"100430894","phase-2-toripalimab-plus-flot-in-locally-advanced-gastric-cancer-100430894","NCT04891016","Toripalimab Plus FLOT in Locally Advanced Gastric Cancer","Toripalimab Combined With FLOT Regimen in Locally Advanced Gastric cancer-a Prospective, Open, Multi-center, Phase Ⅱ Clinical Study","Inclusion Criteria:\n\n* 70 ≥ Age ≥ 18 years regardless of gender\n* Gastric adenocarcinoma confirmed by pathology\n* no distant metastasis and resectable or potentially resectable evaluated by general surgery experts\n* ECOG PS 0-1\n* clinical stage T3\u002F4 or N+ by AJCC 8.0\n* PD-L1 CPS ≥1 (IHC 22C3 pharm Dx assay (Dako))\n* expected lifespan over 3 months\n* Adequate organ function: 1) without growth factor and blood component support in the first 2 weeks of enrollment; 2) Cardiac function: no heart disease or coronary heart disease, grade 1-2; 3) liver function: TBIL ≤ 2ULN, AST ≤ 2.5 ULN, alt ≤ 2.5 ULNX 4 Renal function: cr ≤ 1.25ULN, liver function: TBIL ≤ 2ULN, TBIL ≤ 2.5ULN, alt ≤ 2.5ULN, 4)renal function: cr ≤ 1.25ULN.\n* blood pressure normal or controlled within the normal range by antihypertensive drugs\n* Diabetic patients were treated with hypoglycemic drugs to control fasting blood glucose ≤ 8mmol\u002FL\n* Patients with positive hepatitis B surface antigen need to be tested for quantitative detection of hepatitis B DNA virus. HBV DNA should be less than the upper limit of the normal test value for patients with HBV infection.\n* no other serious diseases conflicting with this study\n* No history of other malignant tumors\n* Women of childbearing age must be tested negative for blood pregnancy test within 7 days before enrollment, and subjects of childbearing age must use appropriate contraceptive measures during the trial and within 6 months after the trial\n* agreement to participate in this study and signed the informed consent form\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Suffered from severe infectious diseases within 4 weeks before entering the group\n* Bronchial asthma requires intermittent use of bronchodilators or medical intervention\n* Due to the use of immunosuppressants before coexisting diseases and the dosage of immunosuppressants ≥ 10mg\u002F, the oral dose of prednisone lasted for more than 2 weeks\n* Clinically obvious cardio-cerebrovascular diseases, including, but not limited to, severe acute myocardial infarction, instability or severe angina pectoris, coronary artery bypass surgery, congestive heart failure, ventricular arrhythmias requiring medical intervention, left ventricular ejection fraction \\\u003C 50%, stroke within 6 months\n* Allergic to any experimental drug and its excipients, or have a history of severe allergy, or are contraindications to experimental drugs\n* Severe mental disorders\n* Abnormal coagulation function (PT \\> 16s, APTT \\> 53s, TT \\> 21s Fib \\\u003C 1.5g\u002FL), bleeding tendency or undergoing thrombolysis or anticoagulation therapy\n* Past or present pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, severe impairment of lung function, etc.\n* Unable to swallow research drugs, chronic diarrhea (including but not limited to irritable bowel syndrome, Crohn's disease, ulcerative colitis) and intestinal obstruction affect drug use and absorption\n* Have a history of immunodeficiency, including positive for HIV, or suffer from other acquired, congenital immunodeficiency diseases, or have a history of organ transplant\n* Other researchers evaluate those who do not meet the criteria for admission",{"count":310,"type":22},[25],"Neoadjuvant chemoimmunotherapy for locally advanced gastric and gastroesophageal junction (G\u002FGEJ) cancer is currently under investigation. Most clinical studies have simply combined chemotherapy with anti-PD-1 therapy without considering the impact of chemotherapy drugs on activated immune cells. We designed this study to explore two different treatment regimens for neoadjuvant chemotherapy in patients with locally advanced G\u002FGEJ cancer. One group received FLOT plus toripalimab on Day 1 of each cycle, every 2 weeks for 4 cycles, followed by surgery; the other group received FLOT plus toripalimab on Day 3 of each cycle, every 3 weeks for 3 cycles, followed by surgery. A total of 69 subjects were enrolled. Preliminary statistical analysis conducted one year after the last subject was enrolled revealed no statistically significant differences in pCR and MPR between the two regimens. The median DFS for both groups has not been reached, and there is no statistically significant difference in DFS between the two groups at present. Further subgroup analysis indicated that among subjects with PD-L1 CPS ≥1, the triweekly group achieved a rate of 42.1%, compared to 29.4% in the biweekly group, with no statistically significant difference between the two groups. However, the incidence of bone marrow suppression was lower in the triweekly group than in the biweekly group. Based on the preliminary findings, we plan to conduct an expanded study and transition to a multicenter clinical trial. This study aims to further validate the efficacy of the triweekly chemoimmunotherapy in patients with PD-L1 CPS ≥1 locally advanced G\u002FGEJ cancer.",[32,31,374],"Locally Advanced Gastric Carcinoma","2024-06-05",{"date":377,"type":39},"2024-06-06",{"date":379,"type":39},"2021-06-25",{"date":381,"type":22},"2028-12-31",{"name":383,"class":384},"Henan Cancer Hospital","OTHER_GOV",{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":390,"acronym":4,"eligibilityCriteria":391,"healthyVolunteers":308,"sex":336,"minAge":4,"maxAge":4,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":47},"100536002","lag3-expression-in-triple-negative-breast-cancer-100536002","NCT06259162","LAG3 Expression in Triple Negative Breast Cancer","The Evaluation the Relationship Between LAG-3 Expression \u002F Immune Checkpoint Protein Expression and Neoadjuvant Chemotherapy Plus Immune Checkpoint Inhibitor in Triple Negative Breast Cancer","Inclusion Criteria:\n\n* Planned neoadjuvant chemotherapy\n* Triple negative breast cancer\n\nExclusion Criteria:\n\n* HER2-positive breast cancer\n* Hormone receptor positive breast cancer",{"count":393,"type":22},128,[288],"This study is the experimental study for relationship between LAG-3 expression \u002F immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.",[397,31],"Triple Negative Breast Cancer","2024-02-06",{"date":400,"type":39},"2024-02-14",{"date":402,"type":39},"2022-11-18",{"date":404,"type":22},"2027-12-31",{"name":406,"class":46},"Samsung Medical Center",{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":23,"phases":416,"briefSummary":417,"conditions":418,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":47},"100528996","covid-19-vaccine-effectiveness-against-recurrent-infection-among-lung-cancer-patients-and-biomarker-research-100528996","NCT06168032","COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research","Efficacy of COVID-19 Booster-Dose Vaccine for Re-infection Precaution and Dynamics of Specific Serum Antibodies in the Management of Lung Cancer Patients With Systemic Anti-cancer Treatment","Inclusion Criteria:\n\n1. Patients who agree to participate in the trial and sign the informed consents.\n2. Male or female, ≥18 years old.\n3. Diagnosed of lung carcinoma by histological and cytological examinations.\n4. Undergoing systemic anti-tumor treatments including chemotherapy, immunotherapy, chemoimmunotherapy and targeted therapy.\n5. Recorded history of COVID19 infection.\n6. Sufficiently functional organs.\n7. Eastern Cooperative Oncology Group performance score (PS) ranging from 0 to 2.\n\nExclusion Criteria:\n\n1. Life expectance less than 3 months.\n2. Less than 3 months since last confirmed COVID-19 infection.\n3. Patients unable to return the hospital for follow-up.\n4. Patients allergic to COVID-19 vaccine.\n5. Patients with histories of severe treatment-related adverse events graded 3rd or higher, including those caused by antitumor therapies or immunization except recoverable granulocytopenia.",{"count":415,"type":22},1224,[288],"A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.",[419,110,420,421,32,31],"COVID-19 Recurrent","Vaccination","Antibody","2023-12-11",{"date":424,"type":39},"2023-12-13",{"date":426,"type":22},"2023-12-08",{"date":428,"type":22},"2026-12-08",{"name":430,"class":46},"Peking Union Medical College Hospital",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":23,"phases":440,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":444,"lastUpdatePostDateStruct":445,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":47},"100527042","phase-2-a-prospective-study-of-pembrolizumab-combining-chemotherapy-in-advanced-nsclc-patients-with-egfr-exon-21-point-mutation-100527042","NCT06142617","A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.","A Phase II Study of Pembrolizumab Plus Platinum and Pemetrexed as First Line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer Patients With EGFR Exon 21 Point Mutation and Programmed Cell Death Ligand 1 Expression","Inclusion Criteria:\n\n1. Male or female, ≥18 years old\n2. Primary non-squamous non-small cell lung cancer(NSCLC) with stage IV (AJCC stage,8th Edition) confirmed by cytology or histology\n3. Patients who have not used any anti-tumor therapy drugs such as targeted drugs, chemotherapy or immunotherapy and patients after surgery are acceptable\n4. EGFR exon 21 point mutation confirmed by gene test of tissue or blood and PD-L1 (22C3) TPS≥1% confirmed by immunohistochemical method\n5. At least one evaluable focus judged according to RECIST 1.1 standard\n6. Eastern Cooperative Oncology Group performance score (PS) 0 or 1\n7. Adequate blood function: absolute neutrophil count (ANC) ≥ 2 × 109 \u002F L, platelet count ≥ 100 × 109 \u002F L and hemoglobin 110 ≥ 9 g \u002F dl. Adequate renal function: serum creatinine ≤ upper limit of normal value. Adequate liver function: total bilirubin ≤ upper limit of normal value(ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ upper limit of normal value (ULN); alkaline phosphatase ≤ upper limit of normal value (ULN)\n8. Life expectancy is not less than 6 months\n9. Male participants: Male participants must take effective contraception and do not donate sperm during the study and 180 days at least after the last dose\n10. Female participants can not be pregnant, breastfeeding, and meet at least one of the following conditions:\n\n    1. non-fertile women or\n    2. agree to use effective contraception during treatment and 180 days at least after the last dose\n    3. Fertile women must perform a serum or urine pregnancy test within 72 hours before the first dose and the results must be negative (minimum sensitivity 25 IU\u002FL or human chorionic gonadotropin (HCG) equivalent unit)\n11. Sign the informed consent form (the informed consent form needs to be approved by the independent ethics committee, and the informed consent of the patient should be obtained before starting any substantive trial procedure)\n\nExclusion Criteria:\n\n1. patients who have active autoimmune disease which needs systemic treatment like disease relievers, corticosteroids, or immunosuppressants) in the last 2 years e. Alternative therapies ( such as thyroxine, insulin, and physiologic corticosteroid replacement therapy of adrenal or pituitary function insufficiency) are permitted)\n2. History of pneumonia (non-infectious)\u002Finterstitial lung disease which require s steroid treatment or a current pneumonia\u002Finterstitial lung disease\n3. Previously diagnosed immunodeficiency diseases, such as immunoglobulin deficiency, aplastic anemia\n4. Known history of human immunodeficiency virus (HIV) infection\n5. Patients who have hepatitis B (defined as hepatitis B virus (HBV) DNA \\> 1000 copy number) and hepatitis C virus (HCV) (defined as HCV RNA (+) infection\n6. Known history of active tuberculosis infection\n7. Patients who received live or attenuated vaccine within 30 days prior to the first study intervention and inactivated vaccines are allowed.\n8. Patients who have other known malignancies within the past 1 year and needs treatment. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ that has undergone potentially curative treatment, and bladder carcinoma in situ are not included.\n9. Patients who have symptomatic central nervous system metastases and\u002For meningitis\n10. History of hypersensitivity ( ≥ Level 3) to pembrolizumab\u002Fpemetrexed\u002Fplatinum\u002Fosimertinib and\u002For any of its excipients\n11. Active infection that requires systemic treatment\n12. Any medical condition that the investigator believes might do harm to the patient or not in the best interest of the patients such as poorly controlled diabetes, infection requiring treatment by injection, liver failure, mental illness or any disease, treatment, laboratory abnormality that might confuse the results or interfere with the participation of patients throughout the study.\n13. Patients with mental illness or substance abuse which are confirmed to interfere with compliance with test requirements\n14. Planed or currently pregnant or lactation during the study (from beginning of the screening visit to 180 days after the last dose of the experimental drug)\n15. Patients who have undergone allogeneic tissue\u002Fsolid organ transplantation\n16. Patients who could not accept regular follow-up\n17. Patients who are participating in or have used other investigational drugs or investigational equipment",{"count":439,"type":22},37,[25],"A phase II, single-arm, open-label study evaluating efficacy, safety and feasibility of combined chemotherapy and pembrolizumab as first line therapy and Osimertinib as second line therapy in advanced non squamous NSCLC adult patients with epidermal growth factor receptor (EGFR) exon 21 point mutation and programmed cell death receptor ligand 1 (PD-L1) positive.",[163,31,443],"EGFR Exon 21 Mutation","2023-11-16",{"date":446,"type":39},"2023-11-21",{"date":448,"type":22},"2023-12-01",{"date":450,"type":22},"2028-06-30",{"name":430,"class":46},{"id":453,"slug":454,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":458,"eligibilityCriteria":459,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":460,"targetDuration":4,"studyType":133,"phases":4,"briefSummary":462,"conditions":463,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":47},"100500718","fast-track-cardiovascular-assessment-for-suspicion-of-cardiovascular-events-on-immunecheckpoint-inhibitors-100500718","NCT05799898","Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors","Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors: Prospective Cohort Study.","FAST-TRACK","Inclusion Criteria:\n\n* all patient referred to the cardio oncology unit for suspected immune related cardiovascular complication on immune checkpoint inhibitors\n\nExclusion Criteria:\n\n* none",{"count":461,"type":22},200,"Prospective study cohort on patients addressed for suspected cardiovascular event on immune checkpoint inchibitors.\n\nLongitudinal prospective single center cohort. Inclusion criteria: all patient willing to particiupate seen in the cardio-oncology unit at our institution for the suspicion of heart failure, atherosclerosis related event, Tako Tsubo, arrhymias, pericarditis, myocarditis on antiPD1, antiPDL1, or antiCTLA4 immune checkpoint inhibitors.\n\nDescription of patients characteristics, investigations, diagnosis after multidisciplinary meeting, outcomes.",[464,31,465,61],"Cancer","Cardiovascular Complication","2023-03-23",{"date":468,"type":39},"2023-04-05",{"date":470,"type":39},"2022-03-01",{"date":472,"type":22},"2030-01-01",{"name":474,"class":46},"Institut Mutualiste Montsouris",{"id":476,"slug":477,"hasResults":11,"nctId":478,"briefTitle":479,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":486,"overallStatus":139,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":495,"locationsCount":47},"100492908","a-pilot-study-to-understand-the-impact-of-therapy-with-tumour-treating-fields-ttfields-in-nsclc-100492908","NCT05698264","A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC","Inclusion Criteria:\n\n1. Male and female patients 18 years of age and older.\n2. Have histologically or cytologically confirmed lung cancer.\n3. Documented next generation sequencing assay performed on tumor sample in Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory.\n4. Have at least 1 measurable lesion per RECIST v1.1\n5. Have life expectancy ≥3 months.\n6. Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n7. Must provide a signed and dated informed consent indicating that the participants have been informed of all pertinent aspects of the study, including the potential risks, and is willingly participating.\n8. Have the willingness and ability to comply with scheduled visits and study procedures.\n9. Cohort A, confirmed EGFR mutation.\n\nExclusion Criteria:\n\n1. Implanted electronic devices (e.g. pacemaker) in the upper torso.\n2. Have been diagnosed with another primary malignancy within the past 3 years (except for adequately treated non-melanoma skin cancer, cervical cancer in situ or prostate cancer, which are allowed within 3 years).\n3. Have any condition or illness that, in the opinion of the investigator, would compromise participants' safety or interfere with the evaluation.\n4. Be pregnant or breastfeeding.",{"count":159,"type":22},[288],"Low intensity, intermediate frequency (100-300 kHz) alternating electric fields, also known as Tumor Treating Fields (TTFields) were found to have a profound inhibitory effect on the growth rate of a variety of human cancer cells. Previous study showed anti-tumor activity in respect of melanoma, glioblastoma (GBM), breast carcinoma and NSCLC cell lines. This study aims to assess the impact of TTFields on NSCLC though the understanding of tumor evolution and peripheral lymphocytes activity and proliferation.\n\nConcomitant to drug therapy, patients will receive treatment with Tumor Treating Fields (TTFields), generated by the medical device NovoTTF-200T with a recommended duration of minimum 18 h a day. TTFields administered using insulated transducer arrays applied to the skin surrounding the region of a malignant tumor.\n\n50 patients will be recruited according to the study design in two cohorts and will receive TTFields therapy: Cohort A: Adult NSCLC EGFR positive mutation. Cohort B: Adult NSCLC patients to be treated with PD-1 inhibitors. The cohort A will focus on the clonal evolution in EGFR mutated lung cancer patients by using circulating tumor DNA (ctDNA) analysis of paired baseline and end-of-treatment (EOT) plasma samples. The cohort B will study the impact of TTField on the profile, activity, and proliferation of peripheral lymphocytes. Lymphocytes will be purified from whole blood samples for the profile, proliferation, and activity analyzed by FACS.\n\nTreatment with TTFields will be administered until progressive disease, unacceptable toxicity1, withdrawal of consent or death. After the end of treatment, the patients will be followed until data cutoff date or 2 years after the last patient had entered the study.",[163,485,31],"EGFR Gene Mutation",[487,114,163,488,485],"TTFields","NSCLC","2023-01-22",{"date":491,"type":39},"2023-01-26",{"date":493,"type":22},"2023-01-20",{"date":381,"type":22},{"name":496,"class":46},"Nir Peled"]